H4ZE:F:F-HSBC MSCI Europe UCITS ETF (EUR)

ETF | Others |

Last Closing

USD 17.146

Change

-0.19 (-1.12)%

Market Cap

N/A

Volume

N/A

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-11-13 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
PRAJ:F Amundi Index Solutions - Amund..

-0.36 (-1.30%)

USD 139.20B
UIM5:F UBS (Lux) Fund Solutions - MSC..

-0.02 (-0.04%)

USD 114.95B
SXR8:F iShares Core S&P 500 UCITS ETF..

+1.54 (+0.26%)

USD 98.13B
ZPDJ:F SPDR® MSCI Japan UCITS ETF

-0.09 (-0.16%)

USD 91.82B
XDNY:F Xtrackers MSCI Japan ESG Scree..

-0.11 (-0.70%)

USD 54.47B
VUSA:F Vanguard Funds Public Limited ..

+0.70 (+0.65%)

USD 51.63B
VUAA:F Vanguard S&P 500 UCITS Acc

+0.53 (+0.49%)

USD 51.63B
SXRZ:F iShares VII PLC - iShares Nikk..

-1.50 (-0.63%)

USD 50.58B
XJSE:F Xtrackers II - Japan Governmen..

-0.01 (-0.11%)

USD 40.89B
0ZC:F Zscaler Inc

+8.46 (+4.34%)

USD 37.92B

ETFs Containing H4ZE:F

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 4.40% 41% F 54% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 4.40% 40% F 54% F
Trailing 12 Months  
Capital Gain 11.01% 47% F 55% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 11.01% 47% F 55% F
Trailing 5 Years  
Capital Gain 23.55% 53% F 60% D-
Dividend Return N/A N/A N/A N/A N/A
Total Return 23.55% 53% F 60% D-
Average Annual (5 Year Horizon)  
Capital Gain 8.89% 68% D+ 65% D
Dividend Return 8.89% 66% D+ 59% D-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 12.69% 53% F 83% B
Risk Adjusted Return 70.04% 77% C+ 82% B
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:

There is nothing we particularly dislike